1998 ; 17 : 101 . 65 Eifel P Axelson JA Costa J . National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3 2000 . J Natl Cancer Inst 2001 ; 93 : 979 . www
Search Results
Ali Raza Khaki, V.K. Gadi, and Vinay Prasad
LA , Davis GJ , . Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer . J Clin Oncol 2001 ; 19 : 980 – 991 . 11181660 10.1200/JCO.2001.19.4.980 2. Wishart GC , Azzato EM , Greenberg
Ami Vyas, S. Suresh Madhavan, and Usha Sambamoorthi
months) after BC diagnosis constituted 37% of BC Medicare spending, which is substantially higher due to surgery and adjuvant therapy. 2 – 6 Additionally, elderly women aged ≥65 years have higher BC incidence compared with their younger counterparts, 7
Andrew L. Ji, Christopher K. Bichakjian, and Susan M. Swetter
predictor of survival and determines the indication for additional surgery (ie, complete lymph node dissection), systemic adjuvant therapy, surveillance imaging, and frequency of clinical follow-up. However, controversy remains regarding the most appropriate
Swaminathan Murugappan, William P. Harris, Christopher G. Willett, and Edward Lin
different benefits were seen from adjuvant therapy. 64 Patients were followed for a median of 4 years, with 41% of patients administered fluoropyrimidine-based adjuvant therapy. Patients with intermediate tumor response benefited the most from adjuvant
Efrat Dotan, Ilene Browner, Arti Hurria, and Crystal Denlinger
was sufficient to warrant consideration of adjuvant chemotherapy. Because cancer was found to be the primary cause of death in this population, adjuvant therapy is likely to improve disease outcomes. The lower rates of adjuvant therapy use among
03689712) is in progress. Clinical trials to reduce RT-related esophagitis are also planned. CLO19-040: The Role of Adjuvant Therapy in Patients With Pathological T2N0 Resected Gastric Adenocarcinoma John Khoury, MD a ; David Macari, MD a ; Daniel Ezekwudo
William J. Gradishar, Benjamin O. Anderson, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, Daniel F. Hayes, Clifford A. Hudis, Steven J. Isakoff, Britt-Marie E. Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Robert S. Miller, Mark Pegram, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Mary Lou Smith, Hatem Soliman, George Somlo, John H. Ward, Antonio C. Wolff, Richard Zellars, Dorothy A. Shead, and Rashmi Kumar
experienced breast surgery team that works in a coordinated, multidisciplinary fashion to guide proper patient selection for skin-sparing mastectomy, determine optimal sequencing of the reconstructive procedures in relation to adjuvant therapies, and perform a
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, Lisa Gurski, and Deborah A. Freedman-Cass
. Preoperative chemoRT may result in tumor downsizing and a decrease in tumor bulk (see “Neoadjuvant and Adjuvant Therapy for Resectable Nonmetastatic Disease,” page 885); sphincter preservation may become possible in cases where initial tumor bulk prevented
Harold J. Burstein
, hopefully unbiased, fashion. Let’s apply this strategy to two important trials in early-stage breast cancer; the HERA study, which compared 0 versus 1 versus 2 years of trastuzumab as adjuvant therapy for HER2-positive breast cancers (the comparison of 1
